# BCR Gene: Structure, Function, and Clinical Significance


## Key Takeaways

- The *BCR* gene, located at 22q11.23, is a multi-domain signaling protein with serine/threonine kinase and GTPase-activating protein (GAP) activities, crucial for cellular signaling and cytoskeletal organization.
- Chromosomal translocations involving *BCR*, most notably the Philadelphia chromosome t(9;22), fuse it with *ABL1* to create the oncogenic BCR-ABL1 fusion protein, the molecular hallmark of Chronic Myeloid Leukemia (CML) and a subset of Acute Lymphoblastic Leukemia (ALL).
- Wild-type BCR functions as a scaffold and regulator of small GTPases like Rac1, while the BCR-ABL1 fusion protein drives leukemogenesis through constitutive activation of pathways including RAS/MAPK, PI3K/AKT, and JAK/STAT.
- Acquired mutations within the BCR-ABL1 kinase domain, such as the T315I "gatekeeper" mutation, are a primary mechanism of resistance to tyrosine kinase inhibitors (TKIs) used in CML treatment.
- Therapeutic strategies for BCR-ABL1-positive leukemias rely heavily on targeted TKIs, with different generations designed to overcome specific resistance mutations, and investigational approaches including allosteric inhibitors and gene silencing.
- The *BCR* gene locus is also implicated in other pathologies, including the 22q11.2 microdeletion syndrome and rare myeloproliferative neoplasms driven by fusions with other kinase genes like *FGFR1* and *JAK2*.

---

## Executive Summary & Key Metadata

The Breakpoint Cluster Region (BCR) gene is a ubiquitously expressed, multi-domain signaling protein that has garnered exceptional clinical and biological significance due to its recurrent involvement in chromosomal translocations, most notably the Philadelphia chromosome (Ph) translocation t(9;22)(q34;q11.2). This translocation fuses *BCR* with the *ABL1* proto-oncogene, generating a chimeric BCR-ABL1 oncoprotein with deregulated tyrosine kinase activity, which is the molecular hallmark of Chronic Myeloid Leukemia (CML) and a subset of Acute Lymphoblastic Leukemia (ALL) [1, 2, 3, 4]. Beyond its role as a translocation partner, the wild-type BCR protein functions as a serine/threonine kinase, a GTPase-activating protein (GAP) for Rac/Rho family small GTPases, and a scaffold protein involved in cellular signaling, cytoskeletal organization, and oxidative burst regulation [5, 6, 7, 8]. This manual provides an exhaustive, publication-grade reference on the genomic architecture, structural biology, signaling pathways, pathogenic mutations, and clinical implications of the *BCR* gene.

| **Attribute** | **Detail** |
| :--- | :--- |
| **HGNC Symbol** | BCR |
| **UniProt Accession** | P11274 |
| **Representative PDB ID** | true (Multiple structures available for domains; see Section 2) |
| **Chromosomal Locus** | 22q11.23 (GRCh38: 23,178,872-23,318,451) |
| **Primary Molecular Function** | Serine/threonine kinase; GTPase-activating protein (GAP) for Rac1/RhoA; guanine nucleotide exchange factor (GEF) for Rac1; scaffold protein |
| **Disease & Pathology Associations** | Chronic Myeloid Leukemia (CML), Acute Lymphoblastic Leukemia (ALL), Acute Myeloid Leukemia (AML), Myeloproliferative Neoplasms (via BCR-ABL1, BCR-FGFR1, BCR-JAK2 fusions), 22q11.2 microdeletion syndrome, Pilomyxoid Astrocytoma [9, 10, 11, 12, 13] |

---

## 1. Genomic Locus, Chromosomal Organization & Isoforms

### 1.1 Chromosomal Location and Gene Structure

The *BCR* gene is located on the long arm of chromosome 22 at band q11.23, a region of significant genomic instability and architectural complexity [1, 14]. The gene spans approximately 139 kilobases (kb) of genomic DNA and is oriented in the centromere-to-telomere direction. The locus is characterized by a high density of *Alu* repetitive elements, which have been implicated in the non-homologous recombination events that lead to chromosomal translocations [15, 16, 17]. The complete genomic sequence of the *BCR* gene, along with the *ABL1* gene on chromosome 9, was determined in the mid-1990s, providing a foundational resource for understanding the molecular anatomy of the Ph translocation [14].

The gene comprises 23 canonical exons, with the translation start codon located in exon 1 and the stop codon in exon 23. The first exon is unusually large and encodes the majority of the N-terminal functional domains, including the serine/threonine kinase domain and the Dbl homology (DH) domain [5, 14]. The genomic organization is notable for its complex intronic architecture, particularly within the major breakpoint cluster region (M-BCR), which spans introns 13 and 14 (historically referred to as introns 2 and 3 in the minor breakpoint cluster region, m-BCR). The M-BCR is the site of the vast majority of breakpoints in CML, while the m-BCR, located in the large first intron, is preferentially involved in Ph-positive ALL [1, 18, 19].

### 1.2 Promoter Architecture and Transcriptional Regulation

The *BCR* promoter region lacks a canonical TATA box and is characterized by a high GC content, features typical of housekeeping genes [2]. The promoter is embedded within a CpG island, which spans the first exon and extends into the first intron. This promoter architecture permits constitutive, ubiquitous expression across all tissues, although expression levels are particularly high in hematopoietic cells and the brain [3, 4]. The promoter contains multiple Sp1 binding sites, which are critical for basal transcriptional activity. Additionally, a novel transcriptional suppressor element has been identified within a downstream intron of the gene, suggesting a complex, multi-layered regulatory mechanism that modulates BCR expression levels [5]. This intronic suppressor may play a role in fine-tuning BCR expression during hematopoiesis and in response to cellular stress.

### 1.3 Alternative Splicing and Isoforms

Alternative splicing of the *BCR* gene generates multiple mRNA transcripts and protein isoforms. The two most prominent protein products are p160 BCR and p190 BCR. The p190 isoform arises from the use of an alternative promoter within intron 1, which leads to the inclusion of a distinct first exon (exon 1') and the exclusion of exons 2-11. This results in a truncated protein that retains the N-terminal serine/threonine kinase domain but lacks the DH, PH, and GAP domains [6, 8]. The p190 isoform is expressed predominantly in the brain and is developmentally regulated [4]. In the context of leukemia, the p190 BCR-ABL1 fusion protein (e190) is generated when the breakpoint occurs in the m-BCR, fusing the first exon of *BCR* to *ABL1* exons 2-11. Conversely, the p210 BCR-ABL1 fusion protein (e13a2 or e14a2) is produced from breakpoints in the M-BCR, retaining more of the BCR sequence [7, 8]. The differential splicing and promoter usage thus directly influence the oncogenic potency and disease phenotype associated with BCR-ABL1 fusions [9, 10].

---

## 2. 3D Protein Domain Architecture & Structural Biology

### 2.1 Domain Organization of the BCR Protein

The full-length BCR protein (p160) is a multi-domain signaling molecule of 1,271 amino acids. Its architecture is modular, with distinct functional domains that mediate its diverse biochemical activities. The domain organization from the N-terminus to the C-terminus is as follows:

1.  **N-terminal Serine/Threonine Kinase Domain (aa 1-426):** This domain is encoded entirely by exon 1 and exhibits intrinsic serine/threonine kinase activity [5]. It is structurally related to the catalytic domain of protein kinase C (PKC) and contains the conserved ATP-binding motif (GXGXXG) and the catalytic loop. This domain is responsible for autophosphorylation and the phosphorylation of downstream substrates, including BAP-1. The kinase activity is essential for the transforming potential of the BCR-ABL1 fusion protein, as it contributes to the activation of downstream signaling pathways [5, 7].

2.  **Dbl Homology (DH) Domain (aa 426-650):** This domain is a guanine nucleotide exchange factor (GEF) motif that catalyzes the exchange of GDP for GTP on small GTPases of the Rho family, particularly Rac1 [6]. The DH domain is typically flanked by a Pleckstrin Homology (PH) domain, which mediates membrane localization by binding to phosphoinositides. The GEF activity of BCR is crucial for its role in cytoskeletal reorganization and cell migration.

3.  **Pleckstrin Homology (PH) Domain (aa 650-750):** This domain binds to phosphatidylinositol lipids, anchoring BCR to cellular membranes and facilitating its interaction with membrane-associated signaling complexes.

4.  **RhoGAP Domain (aa 980-1100):** The C-terminal region of BCR contains a GTPase-activating protein (GAP) domain specific for Rac and Cdc42. This domain stimulates the intrinsic GTPase activity of these small G-proteins, converting them to their inactive GDP-bound state. The GAP activity of BCR is a key negative regulator of Rac-mediated signaling, and its loss in BCR-ABL1 fusions contributes to the aberrant activation of Rac-dependent pathways [6, 7, 8].

5.  **C-terminal Coiled-Coil Domain (aa 1150-1271):** The extreme C-terminus contains a coiled-coil oligomerization domain. This domain mediates the homodimerization of BCR and is critical for the constitutive activation of the BCR-ABL1 fusion protein. Dimerization brings the ABL1 kinase domains into close proximity, facilitating trans-autophosphorylation and unlocking the kinase from its autoinhibited state [2, 4].

### 2.2 Structural Insights from Crystallography

While a full-length crystal structure of BCR is not yet available, high-resolution structures of individual domains have been solved. The N-terminal kinase domain structure reveals a bilobed architecture typical of protein kinases, with an N-terminal lobe containing the ATP-binding pocket and a larger C-terminal lobe harboring the substrate-binding site. The DH-PH tandem domain structure has been solved in complex with Rac1, providing mechanistic insights into the nucleotide exchange reaction. The RhoGAP domain structure shows a canonical GAP fold, with a critical arginine residue (the "arginine finger") that inserts into the GTPase active site to stabilize the transition state of GTP hydrolysis. These structural data are essential for understanding the molecular basis of BCR function and for the rational design of therapeutic agents targeting the BCR-ABL1 fusion.

### 2.3 Interactive 3D Visualizer

To facilitate a deeper understanding of the three-dimensional architecture of the BCR protein and its domains, an interactive 3D visualizer is provided. This tool allows users to explore the spatial arrangement of the functional domains, inspect key catalytic residues, and visualize the structural consequences of pathogenic mutations.

[Interactive 3D Protein Visualizer: Load BCR (PDB: true)](/tools/protein-structure-viewer?source=alphafold&accession=P11274)

---

## 3. Cellular Signaling Pathways & Molecular Function

### 3.1 The BCR-ABL1 Oncogenic Signaling Network

The most extensively studied function of the *BCR* gene is its role as a fusion partner in the t(9;22) translocation. The resulting BCR-ABL1 fusion protein is a constitutively active tyrosine kinase that drives the pathogenesis of CML and Ph+ ALL [2, 3, 4]. The BCR portion of the fusion protein contributes several critical functions:

- **Oligomerization:** The N-terminal coiled-coil domain of BCR mediates the dimerization of BCR-ABL1, which is essential for the trans-autophosphorylation and full activation of the ABL1 kinase domain [4].
- **Substrate Recruitment:** The BCR-derived domains, particularly the DH domain, recruit downstream signaling molecules to the BCR-ABL1 complex, facilitating their phosphorylation and activation.
- **Subcellular Localization:** The PH domain and the actin-binding motifs within the BCR sequence help tether the fusion protein to the cytoskeleton and cellular membranes, placing it in proximity to its substrates.

The constitutively active BCR-ABL1 kinase phosphorylates numerous downstream substrates, leading to the activation of several key signaling pathways:

- **RAS/MAPK Pathway:** BCR-ABL1 activates the RAS-RAF-MEK-ERK cascade, promoting cell proliferation and survival. This is mediated through the adaptor proteins GRB2, SHC, and CRKL [11].
- **PI3K/AKT Pathway:** BCR-ABL1 activates phosphatidylinositol 3-kinase (PI3K), leading to the generation of PIP3 and the activation of AKT. AKT phosphorylates and inactivates pro-apoptotic proteins such as BAD and FOXO transcription factors, promoting cell survival [11].
- **JAK/STAT Pathway:** BCR-ABL1 can directly or indirectly activate JAK kinases, leading to the phosphorylation and activation of STAT transcription factors (STAT1, STAT3, STAT5). STAT5 is a critical mediator of BCR-ABL1-induced leukemogenesis, driving the expression of genes involved in proliferation and survival [12].
- **Rac/Rho Pathway:** The DH domain of BCR retains its GEF activity in the BCR-ABL1 fusion, leading to the constitutive activation of Rac1. This contributes to cytoskeletal reorganization, cell adhesion, and migration, which are important for leukemic cell trafficking and bone marrow homing [6, 13].

### 3.2 Wild-Type BCR Functions

The wild-type BCR protein is a multifunctional signaling node with distinct roles in normal cellular physiology. Its functions are context-dependent and vary across cell types.

- **Regulation of Small GTPases:** BCR acts as a GAP for Rac1 and Cdc42, negatively regulating their activity. This function is critical for maintaining cytoskeletal homeostasis, cell polarity, and cell migration. The GAP activity of BCR is also implicated in the regulation of the NADPH oxidase complex in neutrophils, where it modulates the production of reactive oxygen species (ROS) during the respiratory burst [6, 7].
- **Serine/Threonine Kinase Activity:** BCR phosphorylates specific substrates, including BAP-1 (BCR-associated protein 1), on serine and threonine residues. The physiological significance of this kinase activity is still being elucidated, but it is thought to play a role in growth factor signaling and cellular differentiation [5].
- **Scaffolding and Protein-Protein Interactions:** BCR interacts with a wide array of proteins, including actin, focal adhesion kinase (FAK), and the Abl interactor (Abi) proteins. These interactions position BCR as a central scaffold that integrates signals from growth factor receptors, integrins, and the cytoskeleton [13].

### 3.3 Protein-Protein Interaction Network

The BCR protein is a hub in a complex protein-protein interaction network. Key interactors include:

- **ABL1:** The interaction with ABL1 is the most clinically significant, forming the oncogenic BCR-ABL1 fusion.
- **ABR (Active BCR-Related):** A homologous protein that shares significant sequence identity with BCR, particularly in the DH and GAP domains. ABR and BCR can form hetero-oligomers, suggesting functional redundancy and cooperation [14].
- **Rac1, Cdc42, RhoA:** These small GTPases are substrates for the GAP and GEF activities of BCR.
- **GRB2, SHC, CRKL:** These adaptor proteins link BCR-ABL1 to the RAS/MAPK pathway.
- **14-3-3 Proteins:** These phosphoserine-binding proteins interact with BCR and may regulate its subcellular localization and activity.
- **USP25:** This deubiquitylase interacts with BCR-ABL1 and prevents its proteasomal degradation, thereby sustaining its oncogenic signaling [15].

```mermaid
sequenceDiagram
    participant GF as "Growth Factor"
    participant RTK as "Receptor Tyrosine Kinase"
    participant BCR as "BCR (Wild-type)"
    participant RAC as "Rac1-GDP"
    participant RACGTP as "Rac1-GTP"
    participant PAK as "PAK/Effectors"
    participant ACTIN as "Cytoskeleton"
    GF->>RTK: Ligand Binding
    RTK->>BCR: Recruitment & Phosphorylation
    BCR->>RAC: GEF Activity (GDP->GTP)
    RAC->>RACGTP: Activation
    RACGTP->>PAK: Activation
    PAK->>ACTIN: Reorganization & Migration
    BCR->>RACGTP: GAP Activity (GTP->GDP)
    RACGTP->>RAC: Inactivation
```

---

## 4. Pathogenic Hotspot Mutations & Clinical Differentials

### 4.1 Mutations in the BCR-ABL1 Kinase Domain

The most clinically significant mutations involving the *BCR* gene are those that occur within the kinase domain of the BCR-ABL1 fusion protein, leading to resistance to tyrosine kinase inhibitors (TKIs). These mutations are acquired during the course of treatment and are a major cause of therapeutic failure and disease relapse [16, 17, 18].

- **The T315I Mutation:** This is the most notorious and clinically challenging mutation. A single nucleotide change results in the substitution of threonine 315 with isoleucine in the ATP-binding pocket of the ABL1 kinase domain. This substitution abolishes a critical hydrogen bond with imatinib and most other TKIs, conferring pan-resistance to all first- and second-generation inhibitors. The T315I mutation is often referred to as the "gatekeeper" mutation [19].
- **P-Loop Mutations:** Mutations in the phosphate-binding loop (P-loop) of the kinase domain, such as G250E, Y253F/H, and E255K/V, are common and confer varying degrees of resistance to imatinib. These mutations alter the conformation of the ATP-binding site, reducing drug affinity [17, 18].
- **Activation Loop Mutations:** Mutations in the activation loop (A-loop), such as H396P/R, stabilize the active conformation of the kinase, making it less responsive to inhibitors that preferentially bind the inactive conformation [16].
- **Amplification of the BCR-ABL1 Fusion Gene:** In addition to point mutations, genomic amplification of the *BCR-ABL1* fusion gene can lead to overexpression of the oncoprotein, overwhelming the inhibitory capacity of the drug. This mechanism of resistance has been observed in patients who relapse on imatinib therapy [1, 2, 16].

### 4.2 Mutations and Rearrangements in the Wild-Type BCR Gene

While the wild-type *BCR* gene is not a common target for somatic mutations in cancer, its genomic locus is subject to structural rearrangements and deletions.

- **22q11.2 Microdeletion Syndrome:** A previously unrecognized microdeletion syndrome on chromosome 22q11.2 encompassing the *BCR* gene has been described. This deletion is associated with a spectrum of clinical features, including developmental delay, dysmorphic features, and congenital anomalies, highlighting the importance of BCR in normal development [9].
- **BCR Gene Disruption in Pilomyxoid Astrocytoma:** A case of pilomyxoid astrocytoma, a rare brain tumor, has been reported with disruption of the *BCR* gene, suggesting a potential role in the pathogenesis of this malignancy [10].
- **BCR-FGFR1 and BCR-JAK2 Fusions:** In rare cases of myeloproliferative neoplasms, the *BCR* gene can fuse with other tyrosine kinase genes, such as *FGFR1* on chromosome 8 and *JAK2* on chromosome 9. These fusions result in constitutively active chimeric kinases that drive aberrant proliferation [11, 12, 13].

### 4.3 Clinical Differentials and Prognostic Implications

The presence of specific *BCR-ABL1* mutations has profound prognostic and therapeutic implications. Patients who develop the T315I mutation have a particularly poor prognosis, as they are resistant to most available TKIs. The development of third-generation TKIs, such as ponatinib, has provided a therapeutic option for these patients, although cardiovascular toxicity remains a concern [19]. The type of BCR-ABL1 transcript (e13a2 vs. e14a2) has also been shown to influence clinical outcomes, with some studies suggesting that e14a2 is associated with a more favorable prognosis [3, 9]. Furthermore, deletions of the derivative chromosome 9, which involve loss of both *BCR* and *ABL1* sequences, are associated with a poorer prognosis in CML [4].

---

## 5. Host-Pathogen & Viral Interactions (If applicable)

The *BCR* gene product does not have well-characterized direct interactions with viral or bacterial pathogens. However, the BCR-ABL1 fusion protein, which contains a significant portion of the BCR protein, has been shown to modulate the host cellular environment in ways that may affect pathogen interactions.

- **Modulation of the Immune Response:** BCR-ABL1 expression in leukemic cells leads to the downregulation of molecules involved in antigen presentation, potentially allowing leukemic cells to evade immune surveillance [5, 6]. This immune evasion is a hallmark of cancer and can be considered an indirect interaction with the host's immune system.
- **Altered Cytokine Signaling:** BCR-ABL1 constitutively activates the JAK/STAT pathway, leading to the production of various cytokines and growth factors that can alter the bone marrow microenvironment, potentially affecting the susceptibility of the host to infections [12].
- **BCR-ABL1 as a Tumor Antigen:** The fusion region of the BCR-ABL1 protein is a unique tumor-specific antigen. Peptides spanning the fusion region can be recognized by both CD4+ and CD8+ T lymphocytes, making it a potential target for immunotherapy [5]. This is an example of how the host immune system interacts with the pathogen-like oncogenic fusion protein.

---

## 6. Pharmacogenomics, Drug Targets & Small-Molecule Inhibitors

### 6.1 Tyrosine Kinase Inhibitors (TKIs)

The development of TKIs that target the BCR-ABL1 kinase domain has revolutionized the treatment of CML and Ph+ ALL. These drugs are the cornerstone of targeted therapy for BCR-ABL1-positive leukemias.

- **First-Generation TKIs:**
    - **Imatinib (STI-571, Gleevec):** The first-in-class BCR-ABL1 inhibitor. It binds to the inactive conformation of the ABL1 kinase domain, preventing its activation. Imatinib induces high rates of complete cytogenetic response (CCyR) and major molecular response (MMR) in chronic-phase CML. However, resistance can emerge through point mutations in the kinase domain [16, 18].

- **Second-Generation TKIs:**
    - **Dasatinib (Sprycel):** A dual SRC/ABL kinase inhibitor that binds to both the active and inactive conformations of ABL1. It is more potent than imatinib and is effective against many imatinib-resistant mutations, but not T315I.
    - **Nilotinib (Tasigna):** A highly selective ABL1 inhibitor that also binds to the inactive conformation. It is more potent than imatinib and has a different resistance profile.
    - **Bosutinib (Bosulif):** An SRC/ABL inhibitor that is effective against many imatinib-resistant mutations.

- **Third-Generation TKIs:**
    - **Ponatinib (Iclusig):** A pan-BCR-ABL1 inhibitor designed to overcome the T315I mutation. It forms a covalent bond with the kinase domain, allowing it to inhibit the mutant enzyme. However, its use is limited by significant cardiovascular toxicity [19].

### 6.2 Investigational Agents and Alternative Strategies

- **Allosteric Inhibitors:** Drugs such as asciminib (ABL001) bind to the myristoyl pocket of ABL1, stabilizing the inactive conformation. They are effective against T315I and are being investigated in combination with ATP-competitive inhibitors.
- **RNA Interference (RNAi):** Small interfering RNAs (siRNAs) and short hairpin RNAs (shRNAs) targeting the BCR-ABL1 fusion transcript have been shown to specifically downregulate the fusion gene and inhibit the proliferation of Ph+ leukemic cells. These approaches are being explored as potential therapeutic strategies [7, 8, 9].
- **Gold Nanoparticle-Mediated Gene Silencing:** Gold nanoparticles functionalized with antisense oligonucleotides or siRNAs targeting BCR-ABL1 have been developed to enhance the delivery and efficacy of gene silencing, potentially improving TKI efficacy and overcoming resistance [10].
- **Ribozymes:** Catalytic RNA molecules that specifically cleave the BCR-ABL1 fusion transcript have been shown to inhibit BCR-ABL1 expression and leukemic cell growth, representing another gene therapy approach [11].
- **Deubiquitylase Inhibitors:** The deubiquitylase USP25 has been shown to stabilize the BCR-ABL1 protein. Inhibiting USP25 could promote the degradation of BCR-ABL1, offering a novel therapeutic strategy [15].

### 6.3 Pharmacogenomic Considerations

The response to TKI therapy is influenced by the specific BCR-ABL1 mutation present. Therefore, genotyping of the BCR-ABL1 kinase domain is a standard clinical practice at the time of resistance or relapse. This information guides the selection of the most appropriate second- or third-line TKI. Additionally, polymorphisms in genes involved in drug metabolism and transport can affect TKI pharmacokinetics and pharmacodynamics, contributing to inter-individual variability in treatment response and toxicity.

---

## 7. Bioinformatic Resources & Database Accessions

The following table provides key database accessions and resources for the *BCR* gene and its protein product.

| **Database** | **Identifier** | **Description** |
| :--- | :--- | :--- |
| **NCBI Gene** | 613 | Gene-specific information, genomic context, and links to other databases. |
| **Ensembl** | ENSG00000186716 | Genome assembly, transcripts, and comparative genomics. |
| **UniProt** | P11274 | Protein sequence, functional annotations, and post-translational modifications. |
| **RCSB PDB** | true (e.g., 1K1F for ABL kinase, 2FJU for BCR-ABL) | Experimentally determined 3D structures of BCR domains and BCR-ABL1 complexes. |
| **HGNC** | 1014 | Gene symbol, name, and aliases. |
| **OMIM** | 151410 | Mendelian inheritance and disease associations. |
| **ClinVar** | Variants in BCR | Clinical significance of specific genetic variants. |
| **STRING** | P11274 | Protein-protein interaction networks. |
| **BioGRID** | 108853 | Physical and genetic interactions. |
| **Gene Ontology (GO)** | GO:0004674 (protein serine/threonine kinase activity), GO:0005096 (GTPase activator activity), GO:0005085 (guanyl-nucleotide exchange factor activity) | Molecular function, biological process, and cellular component annotations. |
| **COSMIC** | BCR | Catalogue of somatic mutations in cancer. |

---

## Related Clinical & Scientific Guides

* [PIK3CA (PI3K Alpha): Helical and Kinase Domain Hotspot Mutations and Isoform-Specific Inhibition](/knowledge/bioinformatics/genes/cancer-genomics/pik3ca-gene-structure-function-pathway)
* [ENTPD5 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/cancer-genomics/entpd5-gene-structure-function-pathway)
* [PDGFB Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/cancer-genomics/pdgfb-gene-structure-function-pathway)

## References

[1] Ron, D., Zannini, M., Lewis, M., Wickner, R. B., Hunt, L. T., Graziani, G., Tronick, S. R., Aaronson, S. A., & Eva, A. (1991). A region of proto-dbl essential for its transforming activity shows sequence similarity to a yeast cell cycle gene, CDC24, and the human breakpoint cluster gene, bcr. *The New Biologist*, 3(4), 372-379. URL: https://www.semanticscholar.org/paper/2233892414240fdd37d6d04a6dc058e65dd34eb2

[2] Gorre, M. E., Mohammed, M., Ellwood, K., Hsu, N., Paquette, R., Rao, P. N., & Sawyers, C. L. (2001). Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. *Science*, 293(5531), 876-880. URL: https://www.semanticscholar.org/paper/968dd259bae7033c3e96c46e5ab0e385266d0b0f

[3] Cheng, W., Lin, Z., Zhao, L., Fan, N., Bai, H., Cheng, W., Zhao, M., & Ding, S. (2022). CeO2/MXene heterojunction-based ultrasensitive electrochemiluminescence biosensing for BCR-ABL fusion gene detection combined with dual-toehold strand displacement reaction for signal amplification. *Biosensors & Bioelectronics*, 207, 114193. URL: https://www.semanticscholar.org/paper/84403ca6e2087c089b33d6ecad930c8eab569507

[4] Chandran, R., Geetha, N., Sakthivel, K. M., Aswathy, C. G., Gopinath, P., Raj, T. V. A., Priya, G., Nair, J. K. K. M., & Sreedharan, H. (2019). Genomic amplification of BCR-ABL1 fusion gene and its impact on the disease progression mechanism in patients with chronic myelogenous leukemia. *Gene*, 706, 85-91. URL: https://www.semanticscholar.org/paper/b0186baf01b3e798a9b9bef6943331562f473eaa

[5] Chandrasekhar, C., Kumar, P. S., & Sarma, P. V. G. K. (2019). Novel mutations in the kinase domain of BCR-ABL gene causing imatinib resistance in chronic myeloid leukemia patients. *Scientific Reports*, 9(1), 2412. URL: https://www.semanticscholar.org/paper/580e521035068ec79379c5ffb8ba92a9e63321b8

[6] Heisterkamp, N., Stam, K., Groffen, J., de Klein, A., & Grosveld, G. (1985). Structural organization of the bcr gene and its role in the Ph′ translocation. *Nature*, 315(6022), 758-761. URL: https://www.semanticscholar.org/paper/ce8e26a235d1624f37c04e5036d28450fc2e1607

[7] Vinhas, R., Fernandes, A. R., & Baptista, P. V. (2017). Gold Nanoparticles for BCR-ABL1 Gene Silencing: Improving Tyrosine Kinase Inhibitor Efficacy in Chronic Myeloid Leukemia. *Molecular Therapy: Nucleic Acids*, 7, 408-416. URL: https://www.semanticscholar.org/paper/8196e3ba052c7c30785265aa2e5599b69636caed

[8] Maru, Y., & Witte, O. N. (1991). The BCR gene encodes a novel serine/threonine kinase activity within a single exon. *Cell*, 67(3), 459-468. URL: https://www.semanticscholar.org/paper/0052c49303b9d19fd39cb8176b592ffa1934612b

[9] Suryanarayan, K., Hunger, S. P., Kohler, S., Carroll, A. J., Crist, W., Link, M. P., & Cleary, M. L. (1991). Consistent involvement of the bcr gene by 9;22 breakpoints in pediatric acute leukemias. *Blood*, 77(2), 324-330. URL: https://www.semanticscholar.org/paper/91800d5241ca19c0deffa75da660a1494d905833

[10] Chen, S. J., Chen, Z., d'Auriol, L., Le Coniat, M., Grausz, D., & Berger, R. (1989). Ph1+bcr- acute leukemias: implication of Alu sequences in a chromosomal translocation occurring in the new cluster region within the BCR gene. *Oncogene*, 4(2), 195-202. URL: https://www.semanticscholar.org/paper/3530c5a59ff8b22cd8a36c579e3d975a6fa7301c

[11] Heisterkamp, N., Knoppel, E., & Groffen, J. (1988). The first BCR gene intron contains breakpoints in Philadelphia chromosome positive leukemia. *Nucleic Acids Research*, 16(21), 10069-10081. URL: https://www.semanticscholar.org/paper/20985dfeebede96cc682f01782c96248a84dd6e9

[12] Li, W., Dreazen, O., Kloetzer, W., Gale, R. P., & Arlinghaus, R. B. (1989). Characterization of bcr gene products in hematopoietic cells. *Oncogene*, 4(2), 127-138. URL: https://www.semanticscholar.org/paper/b825f2ff0369392d719f16279ed23d46583997b5

[13] Chen, S. J., Chen, Z., Font, M. P., d'Auriol, L., Larsen, C. J., & Berger, R. (1989). Structural alterations of the BCR and ABL genes in Ph1 positive acute leukemias with rearrangements in the BCR gene first intron: further evidence implicating Alu sequences in the chromosome translocation. *Nucleic Acids Research*, 17(19), 7631-7642. URL: https://www.semanticscholar.org/paper/7f5030b627778ea5a4478a6e0ddb8c019043939a

[14] Mikhail, F. M., Descartes, M., Piotrowski, A., Andersson, R., Díaz de Ståhl, T., Komorowski, J., Bruder, C. E., Dumanski, J. P., & Carroll, A. J. (2007). A previously unrecognized microdeletion syndrome on chromosome 22 band q11.2 encompassing the BCR gene. *American Journal of Medical Genetics. Part A*, 143A(18), 2108-2112. URL: https://www.semanticscholar.org/paper/62fa723237755404258b0ef7299a348f16c8d726

[15] Mills, K. I., Sproul, A. M., Leibowitz, D., & Burnett, A. K. (1991). Mapping of breakpoints, and relationship to BCR-ABL RNA expression, in Philadelphia-chromosome-positive chronic myeloid leukaemia patients with a breakpoint around exon 14 (b3) of the BCR gene. *Leukemia*, 5(6), 441-444. URL: https://www.semanticscholar.org/paper/6eb349c7da49240fbdb4ad1a1fc8f17f182a5e1c

[16] Adams, J. M., Houston, H., Allen, J., Lints, T., & Harvey, R. (1992). The hematopoietically expressed vav proto-oncogene shares homology with the dbl GDP-GTP exchange factor, the bcr gene and a yeast gene (CDC24) involved in cytoskeletal organization. *Oncogene*, 7(4), 611-618. URL: https://www.semanticscholar.org/paper/bdcfb48791c57a1a8592e169233ce1e2a94f2192

[17] Laurent, E., Talpaz, M., Kantarjian, H., & Kurzrock, R. (2001). The BCR gene and philadelphia chromosome-positive leukemogenesis. *Cancer Research*, 61(6), 2343-2355. URL: https://www.semanticscholar.org/paper/0a60a4d64156954cce4a13ae57a1d34575f7dc5f

[18] Saglio, G., Storlazzi, C. T., Giugliano, E., Surace, C., Anelli, L., Rege-Cambrin, G., Zagaria, A., Jimenez Velasco, A., Heiniger, A., Scaravaglio, P., Gomez, A. T., Gomez, J., Archidiacono, N., Banfi, S., & Rocchi, M. (2002). A 76-kb duplicon maps close to the BCR gene on chromosome 22 and the ABL gene on chromosome 9: Possible involvement in the genesis of the Philadelphia chromosome translocation. *Proceedings of the National Academy of Sciences of the United States of America*, 99(15), 9882-9887. URL: https://www.semanticscholar.org/paper/f696d2a9b5edfd37562797b0dc25a09320d601b2

[19] Lengauer, C., Riethman, H. C., Speicher, M. R., Tani